{"schema_version":"secwatch.filing_event.v1","accession":"0001818382-23-000125","form_type":"8-K","ticker":"HUMA","cik":"0001818382","company_name":"Humacyte, Inc.","filed_at":"2023-09-12T23:59:59+00:00","discovered_at":"2026-05-14T18:03:35.412862+00:00","generated_at":"2026-06-10T21:17:42.626709+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"confidence":"high","headline":"Humacyte reports positive Phase 2/3 HAV trauma trial; BLA planned Q4 2023","bullets":["30-day secondary patency 90.2% (extremity pts) vs 81.1% synthetic graft benchmark.","Amputation rate 9.8% and infection rate 2.0%, both lower than synthetic graft rates.","BLA filing for HAV in extremity vascular trauma expected in Q4 2023.","No unexpected safety signals; results from Ukraine cohort also positive.","HAV has RMAT designation, may allow priority review and no post-approval study."],"urls":{"canonical":"https://secwatch.observer/filing/0001818382-23-000125","json":"https://secwatch.observer/filing/0001818382-23-000125.json","markdown":"https://secwatch.observer/filing/0001818382-23-000125.md","text":"https://secwatch.observer/filing/0001818382-23-000125.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/0001818382-23-000125-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1818382/000181838223000125/huma-20230912.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-10T21:17:42.626709+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}